Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is making significant strides in both its pharmaceutical pipeline and commercial portfolio, according to a recent interview with Co-Founder and Executive Co-Chair Anthony Durkacz on The BioMedWire Podcast. Durkacz discussed the company's lead drug candidate, Lucid-MS, which is advancing to a Phase 2 trial in multiple sclerosis (MS) patients, as well as the development and commercial opportunity surrounding unbuzzd(TM), a product designed to accelerate alcohol metabolism.
Lucid-MS is a patented new chemical entity that has shown promise in preclinical models by preventing and reversing myelin degradation, the underlying mechanism of multiple sclerosis. The upcoming Phase 2 trial will be the first time the drug is tested in patients with MS, marking a critical milestone for Quantum BioPharma and potentially offering a new therapeutic approach for a disease that affects millions worldwide. If successful, Lucid-MS could address a significant unmet need in MS treatment, where current therapies primarily manage symptoms rather than target the root cause of myelin damage.
In addition to its pharmaceutical efforts, Quantum BioPharma is capitalizing on the commercial potential of unbuzzd(TM), an over-the-counter product spun out to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.). Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and holds a 7% royalty on sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. This arrangement provides Quantum with a steady revenue stream while allowing it to focus on its core biopharmaceutical research. The company also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, preserving future opportunities in the medical market.
The dual strategy of advancing a high-potential drug candidate while generating near-term revenue from a consumer product positions Quantum BioPharma to create value across both biotech and wellness sectors. The Phase 2 trial for Lucid-MS, if successful, could lead to a breakthrough in MS treatment, while unbuzzd(TM) taps into a growing consumer interest in health and wellness products. For investors, this diversified approach may reduce risk and offer multiple catalysts for growth.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The company's progress is closely followed by investors and industry observers, with updates available in its newsroom at Quantum BioPharma Ltd. and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM). For the full press release, visit https://ibn.fm/ovRTM.
The announcement was disseminated through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire and other services. This broad reach ensures that Quantum BioPharma's developments are communicated to a wide audience of investors, influencers, and the general public.
As Quantum BioPharma continues to advance Lucid-MS and commercialize unbuzzd(TM), the company's ability to execute on both fronts will be key to its long-term success. The Phase 2 trial results and the market reception of unbuzzd(TM) will be critical indicators of the company's potential to deliver value to shareholders and improve patient outcomes.
